Anti-Tumor Necrosis Factor-α Therapy in the Management of Psoriasis and B-Chronic Lymphocytic Leukemia

Publisher： Karger

E-ISSN： 1662-6567|3|1|60-63

ISSN： 1662-6567

Source： Case Reports in Dermatology, Vol.3, Iss.1, 2011-03, pp. : 60-63

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cutaneous Manifestations in Inflammatory Bowel Diseases: Eight Cases of Psoriasis Induced by Anti-Tumor-Necrosis-Factor Antibody Therapy

By  

Dermatology, Vol. 215, Iss. 4, 2007-10 ,pp. : 295-300

Karger

Access to resources Recommend Favorite

Autoimmune Bullous Skin Diseases Occurring under Anti-Tumor Necrosis Factor Therapy: Two Case Reports

By  

Dermatology, Vol. 221, Iss. 3, 2010-08 ,pp. : 201-205

Karger

Access to resources Recommend Favorite

Paradoxical Reaction to Golimumab: Tumor Necrosis Factor α Inhibitor Inducing Psoriasis Pustulosa

By  

Case Reports in Dermatology, Vol. 5, Iss. 3, 2013-11 ,pp. : 326-331

Karger

Access to resources Recommend Favorite

Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study

By  

Dermatology, Vol. 225, Iss. 4, 2012-12 ,pp. : 312-319

Karger

Access to resources Recommend Favorite

Anti-TNF-α Therapy in Childhood Pustular Psoriasis

By  

Dermatology, Vol. 213, Iss. 4, 2006-12 ,pp. : 350-352

Karger

Access to resources Recommend Favorite